PTC Therapeutics Inc

4 de nov. de 2026, 20:26 UTC

PTC Therapeutics shares are modestly higher, supported by advances in the iShares Biotechnology ETF following positive news on Moderna's mRNA vaccine candidate.

3 de nov. de 2026, 21:02 UTC

PTC Therapeutics' Board approved a $500 million share repurchase program, reflecting confidence in growth prospects and generating positive sentiment around the stock.

2 de nov. de 2026, 21:09 UTC

Citigroup reaffirms Buy rating on PTC Therapeutics and raises price target to $109, as the company prepares for upcoming investor conferences.

30 de out. de 2026, 20:04 UTC

PTC Therapeutics reported a Q3 2026 net loss of $51.7 million and a basic EPS of -$0.62, overshadowing positive analyst ratings and price target increases.

29 de out. de 2026, 20:13 UTC

PTC Therapeutics reported a Q3 2026 net loss of $51.7 million, missing EPS estimates despite revenue of $358 million and raising full-year guidance to $1.29 to $1.32 billion.

28 de out. de 2026, 19:36 UTC

PTC Therapeutics, Inc. is trading higher, having reached a peak cumulative return, consistent with three consecutive daily advances.

27 de out. de 2026, 20:07 UTC

PTC Therapeutics is trading higher, supported by positive momentum in the biotechnology sector and gains in the SPDR S&P Biotech ETF.

23 de out. de 2026, 20:01 UTC

PTC Therapeutics Inc shares are declining, reversing the recent trend of higher daily closes since Thursday's close.

20 de out. de 2026, 20:08 UTC

PTC Therapeutics Inc is advancing, reflecting a broader positive trend in biotechnology stocks as the SPDR S&P Biotech ETF (XBI) also moves higher.

19 de out. de 2026, 20:01 UTC

PTC Therapeutics Inc shares are advancing despite a broader market downturn, continuing the upward momentum observed in recent sessions.

15 de out. de 2026, 20:02 UTC

UBS analyst Joon Lee raised the price target on PTC Therapeutics Inc to $90.00 from $80.00 while maintaining a Buy rating.

13 de out. de 2026, 20:01 UTC

PTC Therapeutics Inc shares fell sharply, continuing a decline near the low end of their one-month range and below the 20-day moving average.

9 de out. de 2026, 20:01 UTC

PTC Therapeutics Inc shares are advancing, recovering from an earlier dip, as the iShares Biotechnology ETF also rises, supported by strong gains in key holdings.

8 de out. de 2026, 20:07 UTC

RBC Capital maintains its Sector Perform rating on PTC Therapeutics and lowers its price target to $75, contributing to the stock's decline.

6 de out. de 2026, 20:07 UTC

PTC Therapeutics Inc's shares are trading roughly flat, retracing from earlier gains and remaining below the 20-day moving average amid a routine biotechnology sector performance.

28 de set. de 2026, 20:01 UTC

PTC Therapeutics Inc. is higher in Monday's trading session, continuing gains since Friday's close, despite an earlier pullback from a session high.

25 de set. de 2026, 20:01 UTC

PTC Therapeutics Inc is advancing as the broader market gains, despite earlier pulling back from a session high amid rising Treasury yields and weak consumer sentiment.

24 de set. de 2026, 20:07 UTC

PTC Therapeutics Inc. shares fell, closing below the 20-day moving average and near the lower end of its one-month range after midday fluctuations.

23 de set. de 2026, 20:02 UTC

PTC Therapeutics Inc shares fell sharply amid a broader downturn in the biotechnology sector, influenced by significant losses in the Direxion Daily S&P Biotech Bull 3X ETF.

18 de set. de 2026, 20:02 UTC

PTC Therapeutics Inc shares fell sharply, reversing a trend of higher daily closes seen in recent sessions, despite no specific news impacting the company.

16 de set. de 2026, 19:06 UTC

PTC Therapeutics gained after Leerink Partners initiated coverage with an "outperform" rating and a $98.00 price target, while Jefferies and Citigroup upgraded their ratings.

14 de set. de 2026, 20:08 UTC

Leerink has initiated coverage on PTC Therapeutics with an Outperform rating and a $98.00 price target, supporting a higher trading session since Friday's close.

11 de set. de 2026, 19:56 UTC

PTC Therapeutics Inc shares are lower today amid discussions from an investor event and plans for a Biologics License Application for a Fabry disease treatment.

10 de set. de 2026, 23:41 UTC

PTC Therapeutics Inc shares are higher in after-market trading, gradually increasing since Thursday's close, despite remaining below their 20-day moving average.

8 de set. de 2026, 20:07 UTC

Shares lower amid decline in iShares Biotechnology ETF.

2 de set. de 2026, 20:08 UTC

PTC Therapeutics Inc. is gaining today, supported by a broader advance in biotechnology stocks, despite a pullback earlier in the session.

31 de ago. de 2026, 19:46 UTC

PTC Therapeutics shares are lower today, continuing a recent decline amid broader market unease following hawkish comments from Federal Reserve Chair Kevin Warsh.

28 de ago. de 2026, 23:36 UTC

PTC Therapeutics Inc shares are higher in after-market hours, recovering from an earlier dip. No specific news was identified to explain the movement.

27 de ago. de 2026, 20:07 UTC

PTC Therapeutics shares are lower today, continuing a decline since Wednesday's close, despite positive labor market data. No specific news was identified.

25 de ago. de 2026, 20:09 UTC

PTC Therapeutics shares are higher as the company announces multiple data presentations for Sephience™ at an upcoming symposium in Helsinki.